Follow
Hao Liu
Hao Liu
US Food and Drug Administration
Verified email at mail.umkc.edu
Title
Cited by
Cited by
Year
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
CK Liu C, Zhang L, Liu H
J Control Release, 17-26, 2017
5062017
Enzyme-Responsive Polymeric Micelles of Cabazitaxel for Prostate Cancer Targeted Therapy
KC Ashutosh Barve, Akshay Jain, Hao Liu, Zhen Zhao
Acta Biomaterialia, 2020
1032020
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
KC Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei ...
Journal for ImmunoTherapy of Cancer, 2019
892019
Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis
CK Chen Z, Jain A, Liu H, Zhao Z
Journal of Pharmacology and Experimental Therapeutics 370 (3), 2019
782019
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
KC Zhen Zhao, Yuanke Li, Hao Liu, Akshay Jain, Pratikkumar Vinodchandra Patel
Science Advances 6, 2020
572020
Development of a Peptide-Modified siRNA Nanocomplex for Hepatic Stellate Cells
KC Zhen Zhao, Yuanke Li, Akshay Jain, Zhijin Chen, Hao Liu, Wei Jin
Nanomedicine: Nanotechnology, Biology and Medicine, 2017
51*2017
Discovery of PSMA-Specific Peptide Ligands for Targeted Drug Delivery
KC Wei Jin, Bin Qin, Zhijin Chen, Hao Liu, Ashutosh Barve
International Journal of Pharmaceutics, 2016
472016
Development of a biocompatible copolymer nanocomplex to deliver VEGF siRNA for triple negative breast cancer
Z Zhao, Y Li, R Shukla, H Liu, A Jain, A Barve, K Cheng
Theranostics 9 (15), 4508, 2019
442019
Discovery of Peptide ligands for hepatic stellate cells using phage display.
CK Chen Z, Jin W, Liu H, Zhao Z
Mol Pharm. 12 (6), 2180-2188, 2015
422015
Discovery of aptamer ligands for hepatic stellate cells using SELEX
Z Chen, H Liu, A Jain, L Zhang, C Liu, K Cheng
Theranostics 7 (12), 2982, 2017
372017
Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma
KC Yuanke Li, Zhen Zhao, Hao Liu, John Peter Fetse, Akshay Jain, Chien-Yu Lin
ACS Appl. Mater. Interfaces, 2019
342019
An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer
KC Ashutosh Barve, Akshay Jain, Hao Liu, Wei Jin
Nanomedicine: Nanotechnology, Biology and Medicine 12 (8), 2373-2381, 2016
322016
Distinguishing Pharmacokinetics of Marketed Nanomedicine Formulations Using a Stable Isotope Tracer Assay
SLSKSSRMCDKXJHLST Stern
ACS Pharmacology & Translational Science, 2020
222020
Targeted delivery of an siRNA/PNA hybrid nanocomplex reverses carbon tetrachloride‐induced liver fibrosis
A Jain, A Barve, Z Zhao, JP Fetse, H Liu, Y Li, K Cheng
Advanced therapeutics 2 (8), 1900046, 2019
222019
Silencing of α-complex protein-2 reverses alcohol-and cytokine-induced fibrogenesis in hepatic stellate cells
KC H Liu, Z Chen, W Jin, A Barve, YJY Wan
Liver Research, 2017
182017
Discovery of cyclic peptide inhibitors targeting PD-L1 for cancer immunotherapy
J Fetse, Z Zhao, H Liu, UF Mamani, B Mustafa, P Adhikary, M Ibrahim, ...
Journal of medicinal chemistry 65 (18), 12002-12013, 2022
152022
Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
GLKC Hao Liu, Yanli Liu, Zhen Zhao, Yuanke Li, Bahaa Mustafa, Zhijin Chen ...
Front. Immunol., 2022
72022
Noncovalent Attachment of Chemical Moieties to siRNA Using Peptide Nucleic Acid As a Complementary Linker
KC W Jin, A Jain, H Liu, Z Zhao
ACS Applied Bio Materials, 2018
42018
Polypeptides And Compositions Comprising The Same
K Cheng, H Liu, J Fetse, UF Mamani
US Patent App. 17/507,301, 2022
2022
Evaluation of the Anti-fibrotic Activity of PCBP2 siRNA in Primary Hepatic Stellate Cells and Discovery of Anti-PD-L1 Peptide and Nanobody for Immunotherapy
H Liu
University of Missouri-Kansas City, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–20